Science to Consumers, Inc. (BEUT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.11: the stock has moved about 89% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerScience to Consumers, Inc. (BEUT) trades at $0.0002. Science to Consumers, Inc. is a development stage company focused on marketing anti-aging cream and distributing Argan oil products. Sector: Consumer staples.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for BEUT: BEUT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Science to Consumers, Inc. (BEUT) Consumer Business Overview
Science to Consumers, Inc., operating in the consumer defensive sector, is a development stage company focused on marketing anti-aging cream under the DermaLastyl name and distributing Argan oil. Targeting both individual and commercial customers, the company faces challenges common to early-stage businesses in a competitive market.
What Is the Investment Thesis for BEUT?
Science to Consumers, Inc. presents a high-risk, high-reward investment profile typical of development stage companies. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's financial performance is currently not indicative of profitability. Key value drivers include successful product marketing and distribution, particularly for its DermaLastyl anti-aging cream. Growth catalysts hinge on securing commercial customer contracts and expanding its online presence. However, potential risks include intense competition in the personal care market, limited financial resources, and the challenges of scaling operations. Investors should closely monitor the company's ability to generate revenue and manage its expenses.
Based on FMP financials and quantitative analysis
BEUT Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources.
- P/E ratio of -0.05 reflects the company's current lack of profitability.
- Beta of 0.11 suggests the stock is less volatile than the overall market.
- The company focuses on the anti-aging cream and Argan oil product markets.
- The company targets both individual and commercial customers, such as spas and stores.
Who Are BEUT's Competitors?
BEUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MTEX Mannatech, Incorporated | $7.43 | +11.90% | $12.8M | 39 5-pillar |
| UG United-Guardian, Inc. | $7.00 | -1.82% | $32.8M | 77 5-pillar |
| AXIL AXIL Brands, Inc. | $6.09 | -1.30% | $42.1M | 60 5-pillar |
| GROV Grove Collaborative Holdings, Inc. | $1.04 | 0.00% | $43.7M | — |
| SLSN Solésence, Inc. | $0.81 | -1.28% | $57.9M | — |
| SKIN The Beauty Health Company | $0.60 | -4.76% | $81.7M | — |
| NUS Nu Skin Enterprises, Inc. | $4.63 | +0.43% | $224M | 49 5-pillar |
| ACU Acme United Corporation | $63.70 | +0.31% | $242M | 79 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BEUT's Key Strengths?
Proprietary DermaLastyl anti-aging cream formulation.
- Targeting both individual and commercial customers.
- Distribution of Argan oil products.
- Focus on a growing anti-aging market.
What Are BEUT's Weaknesses?
Development stage company with limited resources.
- Dependence on a small product line.
- Limited brand recognition.
- Single employee.
What Are the Key Risks for BEUT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the personal care market.
- Limited financial resources to support marketing and product development.
- Changing consumer preferences and trends in the skincare industry.
- Dependence on a small product line and limited customer base.
- Regulatory compliance and potential legal challenges.
What Are BEUT's Competitive Advantages?
- Proprietary DermaLastyl anti-aging cream formulation.
- Established distribution channels with spas and stores.
- Brand recognition in the anti-aging skincare market.
- First-mover advantage in specific niche markets.
What Does BEUT Do?
Science to Consumers, Inc., founded in 2013 and based in Guangzhou, China, is a development stage company operating within the household and personal products industry. Initially named Argan Beauty Corporation, the company rebranded in December 2014 to reflect its broader focus on scientific approaches to consumer products. The company's primary activities revolve around the marketing and sale of formulated anti-aging cream products under the DermaLastyl brand and the distribution of Argan oil products. Science to Consumers, Inc. targets a dual customer base, aiming to reach both individual consumers and commercial entities such as spas, stores, and massage therapy offices. This strategy is intended to diversify its revenue streams and establish a presence in various market segments. As a development stage company, Science to Consumers, Inc. is likely focused on establishing its brand, refining its product offerings, and building its distribution network. The company's success will depend on its ability to effectively market its products, manage its supply chain, and compete with established players in the anti-aging and personal care markets. The company currently has one employee.
What Products and Services Does BEUT Offer?
- Markets and sells anti-aging cream products under the DermaLastyl name.
- Distributes Argan oil products.
- Targets individual customers seeking anti-aging solutions.
- Aims to sell to commercial customers like spas and stores.
- Focuses on formulating and distributing skincare products.
- Operates as a development stage company.
How Does BEUT Make Money?
- Sells anti-aging cream products directly to consumers.
- Distributes Argan oil through various channels.
- Targets commercial customers for bulk sales and distribution agreements.
What Industry Does BEUT Operate In?
Science to Consumers, Inc. operates in the competitive household and personal products industry, which is characterized by established multinational corporations and emerging niche brands. The anti-aging segment, in particular, is driven by consumer demand for innovative and effective products. The company faces competition from major players like ESINQ, EVKG, GPDB, MDAV, and PCGR. Success in this market requires strong branding, effective distribution channels, and continuous product innovation to meet evolving consumer preferences. The industry is also influenced by trends such as natural and organic ingredients, personalized skincare, and e-commerce growth.
Who Are BEUT's Key Customers?
- Individual consumers seeking anti-aging skincare solutions.
- Spas and salons offering skincare treatments.
- Retail stores selling personal care products.
- Massage therapy offices using Argan oil.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Science to Consumers, Inc. operates in the Household & Personal Products industry within the Consumer Defensive sector. It is headquartered in Guangzhou, CN. The company is led by CEO Ensley Edwon Lam. BEUT has traded publicly since 2014.
Key Financial Metrics
Return on equity for Science to Consumers, Inc. stands at 196.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Science to Consumers, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BEUT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BEUT Latest News
No recent news available for BEUT.
BEUT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BEUT.
Price Targets
Wall Street price target analysis for BEUT.
BEUT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BEUT; grades run from A+ (80-100) to F (below 30).
Leadership: Ensley Edwon Lam
CEO
Ensley Edwon Lam serves as the CEO of Science to Consumers, Inc. As the company manages a single employee, Lam's role likely encompasses a wide range of responsibilities, from strategic planning and product development to marketing and sales. Lam's leadership is critical to the company's success, given its early stage and limited resources.
Track Record: Given the company's development stage and limited information available, it is difficult to assess Ensley Edwon Lam's track record. Key milestones under Lam's leadership would include securing initial funding, developing the DermaLastyl anti-aging cream formulation, establishing distribution channels, and generating revenue. The company's future performance will depend heavily on Lam's ability to execute its business plan and navigate the challenges of a competitive market.
BEUT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited or no financial disclosure.
- Low trading volume and liquidity.
- Higher risk of fraud and manipulation.
- Lack of regulatory oversight.
- Potential for delisting and loss of investment.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Check for any regulatory actions or legal issues.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company registration and legal compliance.
- Availability of some financial information, even if limited.
- Active website and communication channels.
- Positive customer reviews or testimonials (if available).
- Industry partnerships or affiliations (if any).
Common Questions About BEUT (Consumer Staples)
What does Science to Consumers, Inc. do?
Science to Consumers, Inc. is a development stage company that focuses on the formulation, marketing, and sale of anti-aging cream products under the DermaLastyl brand, as well as the distribution of Argan oil.
What do analysts say about BEUT stock?
As a development stage company trading on the OTC market, Science to Consumers, Inc. (BEUT) currently lacks analyst coverage. Key valuation metrics such as revenue growth, profitability, and cash flow are limited or unavailable.
What are the main risks for BEUT?
Science to Consumers, Inc. faces several key risks, including intense competition in the personal care market, limited financial resources, and dependence on a small product line.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market carries higher risks than major exchanges.